fbpx

News

Lundbeckfonden Ventures News

Proceeds to enable clinical Phase 2 Proof-of-Concept studies for two lead compounds - a histamine H4 receptor antagonist for atopic dermatitis and a topical cPLA2 inhibitor for psoriasis
Nexstim Plc (Nexstim” or the “Company”) published its initial public offering (the “Offering”) on 13 October 2014, in which the Company offered for subscription up to 2,873,563 new shares. The Company also announced that it will apply for listing of its shares on Nasdaq First North Finland and Nasdaq First North Sweden. The submission of...
Agreement enhances existing relationship between Celladon and Lonza for the manufacture of MYDICAR®Lonza to initiate design of a new commercial viral therapeutics facility in Portsmouth, NH (USA)         Celladon obtains option to trigger construction of facility and commit to long-term commercial supplyLonza to purchase $10 million of Celladon common stock upon Celladon's decision to trigger construction...
Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that the U.S. Food and Drug Administration has informed Veloxis of the tentative approval of Envarsus® XR.  FDA stated that the final approval of Envarsus XR will be delayed until expiration of the exclusivity period for Astellas' Astagraf XL®.  Veloxis understands that this expiry is anticipated to occur...
New Gene Therapy Approach Shown to Reverse Heart Damage and Improve Long Term Cardiac Function Following Myocardial Infarction in Animal Models
Cambridge, Mass., October 15, 2014 - Cydan Development, Inc., an orphan drug accelerator that identifies and de-risks programs with significant therapeutic and commercial potential, today announced the appointment of Vered Bisker-Leib, Ph.D., MBA, as Chief Business Officer. Dr. Bisker-Leib brings a proven track record of identifying, evaluating and executing business development activities in top-tier companies,...
Cambridge, UK - 7th October 2014: Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV...
Ness Ziona, Israel - September 29, 2014 - Atox Bio, a clinical stage company developing novel immunemodulators for severe infections, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Atox Bio with a contract valued up to $24 million and 4.5 years for the development of AB103 to treat Necrotizing Soft...
New Data presented at the 33rd annual meeting of The European Bone & Joint Society (EBJIS) Lund, Sweden, (PRNEWSWIRE) September 23, 2014 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced new twelve.months follow-up data from an on-going clinical trial investigating...
1 43 44 45 46 47 63

Lundbeckfonden Ventures

News

Acacia Pharma Group PLC – Acacia Pharma to Announce its Results for the Full Year 2019 on 2 March 2020 and Provides Notice of its Annual General Meeting
27. February 2020
Acacia Pharma Group PLC – Acacia Pharma Announces US FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV)
27. February 2020
Spero Therapeutics to Present at March Investor Conferences
27. February 2020